SARTORIUS AG-VORZUG (SRT3.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:SRT3 • DE0007165631

239.9 EUR
-1.7 (-0.7%)
Last: Feb 6, 2026, 05:29 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SRT3. SRT3 was compared to 18 industry peers in the Life Sciences Tools & Services industry. SRT3 may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, SRT3 is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • SRT3 had positive earnings in the past year.
  • In the past year SRT3 had a positive cash flow from operations.
  • In the past 5 years SRT3 has always been profitable.
  • Each year in the past 5 years SRT3 had a positive operating cash flow.
SRT3.DE Yearly Net Income VS EBIT VS OCF VS FCFSRT3.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

  • With a Return On Assets value of 1.39%, SRT3 is not doing good in the industry: 72.22% of the companies in the same industry are doing better.
  • Looking at the Return On Equity, with a value of 5.01%, SRT3 is doing worse than 66.67% of the companies in the same industry.
  • SRT3's Return On Invested Capital of 4.71% is on the low side compared to the rest of the industry. SRT3 is outperformed by 72.22% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for SRT3 is in line with the industry average of 9.98%.
Industry RankSector Rank
ROA 1.39%
ROE 5.01%
ROIC 4.71%
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
SRT3.DE Yearly ROA, ROE, ROICSRT3.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

  • The Profit Margin of SRT3 (3.80%) is worse than 72.22% of its industry peers.
  • In the last couple of years the Profit Margin of SRT3 has declined.
  • SRT3's Operating Margin of 14.06% is on the low side compared to the rest of the industry. SRT3 is outperformed by 66.67% of its industry peers.
  • In the last couple of years the Operating Margin of SRT3 has declined.
  • Looking at the Gross Margin, with a value of 46.48%, SRT3 is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
  • In the last couple of years the Gross Margin of SRT3 has declined.
Industry RankSector Rank
OM 14.06%
PM (TTM) 3.8%
GM 46.48%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
SRT3.DE Yearly Profit, Operating, Gross MarginsSRT3.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

1

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SRT3 is destroying value.
  • Compared to 1 year ago, SRT3 has more shares outstanding
  • The number of shares outstanding for SRT3 has been increased compared to 5 years ago.
  • SRT3 has a better debt/assets ratio than last year.
SRT3.DE Yearly Shares OutstandingSRT3.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SRT3.DE Yearly Total Debt VS Total AssetsSRT3.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

  • An Altman-Z score of 2.43 indicates that SRT3 is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • With a Altman-Z score value of 2.43, SRT3 perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
  • SRT3 has a debt to FCF ratio of 8.92. This is a slightly negative value and a sign of low solvency as SRT3 would need 8.92 years to pay back of all of its debts.
  • SRT3's Debt to FCF ratio of 8.92 is on the low side compared to the rest of the industry. SRT3 is outperformed by 66.67% of its industry peers.
  • SRT3 has a Debt/Equity ratio of 1.28. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 1.28, SRT3 is doing worse than 72.22% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.28
Debt/FCF 8.92
Altman-Z 2.43
ROIC/WACC0.53
WACC8.87%
SRT3.DE Yearly LT Debt VS Equity VS FCFSRT3.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.3 Liquidity

  • A Current Ratio of 0.95 indicates that SRT3 may have some problems paying its short term obligations.
  • SRT3's Current ratio of 0.95 is on the low side compared to the rest of the industry. SRT3 is outperformed by 83.33% of its industry peers.
  • A Quick Ratio of 0.49 indicates that SRT3 may have some problems paying its short term obligations.
  • The Quick ratio of SRT3 (0.49) is worse than 88.89% of its industry peers.
Industry RankSector Rank
Current Ratio 0.95
Quick Ratio 0.49
SRT3.DE Yearly Current Assets VS Current LiabilitesSRT3.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 59.34% over the past year.
  • SRT3 shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -11.87% yearly.
  • Looking at the last year, SRT3 shows a small growth in Revenue. The Revenue has grown by 5.82% in the last year.
  • Measured over the past years, SRT3 shows a quite strong growth in Revenue. The Revenue has been growing by 13.10% on average per year.
EPS 1Y (TTM)59.34%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%24.14%
Revenue 1Y (TTM)5.82%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%6.25%

3.2 Future

  • The Earnings Per Share is expected to grow by 18.87% on average over the next years. This is quite good.
  • Based on estimates for the next years, SRT3 will show a quite strong growth in Revenue. The Revenue will grow by 8.45% on average per year.
EPS Next Y23.18%
EPS Next 2Y21.51%
EPS Next 3Y21.15%
EPS Next 5Y18.87%
Revenue Next Year5.32%
Revenue Next 2Y6.73%
Revenue Next 3Y8.71%
Revenue Next 5Y8.45%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SRT3.DE Yearly Revenue VS EstimatesSRT3.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
SRT3.DE Yearly EPS VS EstimatesSRT3.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15

1

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 52.61, the valuation of SRT3 can be described as expensive.
  • Based on the Price/Earnings ratio, SRT3 is valued a bit more expensive than the industry average as 77.78% of the companies are valued more cheaply.
  • When comparing the Price/Earnings ratio of SRT3 to the average of the S&P500 Index (27.92), we can say SRT3 is valued expensively.
  • The Price/Forward Earnings ratio is 39.65, which means the current valuation is very expensive for SRT3.
  • Based on the Price/Forward Earnings ratio, SRT3 is valued a bit more expensive than the industry average as 77.78% of the companies are valued more cheaply.
  • The average S&P500 Price/Forward Earnings ratio is at 27.78. SRT3 is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE 52.61
Fwd PE 39.65
SRT3.DE Price Earnings VS Forward Price EarningsSRT3.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • SRT3's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. SRT3 is more expensive than 61.11% of the companies in the same industry.
  • SRT3's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 37.53
EV/EBITDA 23.72
SRT3.DE Per share dataSRT3.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • SRT3's earnings are expected to grow with 21.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.27
PEG (5Y)N/A
EPS Next 2Y21.51%
EPS Next 3Y21.15%

4

5. Dividend

5.1 Amount

  • SRT3 has a yearly dividend return of 0.39%, which is pretty low.
  • SRT3's Dividend Yield is a higher than the industry average which is at 0.43.
  • Compared to an average S&P500 Dividend Yield of 1.83, SRT3's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.39%

5.2 History

  • The dividend of SRT3 has a limited annual growth rate of 3.71%.
Dividend Growth(5Y)3.71%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • SRT3 pays out 37.92% of its income as dividend. This is a sustainable payout ratio.
  • The dividend of SRT3 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP37.92%
EPS Next 2Y21.51%
EPS Next 3Y21.15%
SRT3.DE Yearly Income VS Free CF VS DividendSRT3.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
SRT3.DE Dividend Payout.SRT3.DE Dividend Payout, showing the Payout Ratio.SRT3.DE Dividend Payout.PayoutRetained Earnings

SARTORIUS AG-VORZUG

FRA:SRT3 (2/6/2026, 5:29:09 PM)

239.9

-1.7 (-0.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-03
Earnings (Next)04-23
Inst Owners4.42%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap17.96B
Revenue(TTM)3.52B
Net Income(TTM)133.70M
Analysts80
Price Target381.28 (58.93%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.39%
Yearly Dividend0.74
Dividend Growth(5Y)3.71%
DP37.92%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.85%
Min EPS beat(2)-10.52%
Max EPS beat(2)4.83%
EPS beat(4)1
Avg EPS beat(4)-3.47%
Min EPS beat(4)-10.52%
Max EPS beat(4)4.83%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.05%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)0.83%
Revenue beat(4)3
Avg Revenue beat(4)1.91%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)4.87%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.46%
PT rev (3m)17.14%
EPS NQ rev (1m)-3.33%
EPS NQ rev (3m)-3.33%
EPS NY rev (1m)0.42%
EPS NY rev (3m)-0.07%
Revenue NQ rev (1m)-0.96%
Revenue NQ rev (3m)-0.96%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.17%
Valuation
Industry RankSector Rank
PE 52.61
Fwd PE 39.65
P/S 5.11
P/FCF 37.53
P/OCF 20.55
P/B 6.73
P/tB N/A
EV/EBITDA 23.72
EPS(TTM)4.56
EY1.9%
EPS(NY)6.05
Fwd EY2.52%
FCF(TTM)6.39
FCFY2.66%
OCF(TTM)11.68
OCFY4.87%
SpS46.97
BVpS35.63
TBVpS-35.24
PEG (NY)2.27
PEG (5Y)N/A
Graham Number60.46
Profitability
Industry RankSector Rank
ROA 1.39%
ROE 5.01%
ROCE 6.33%
ROIC 4.71%
ROICexc 4.98%
ROICexgc 17.77%
OM 14.06%
PM (TTM) 3.8%
GM 46.48%
FCFM 13.61%
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
ROICexc(3y)8.77%
ROICexc(5y)11.17%
ROICexgc(3y)24.37%
ROICexgc(5y)31.52%
ROCE(3y)11.22%
ROCE(5y)14.06%
ROICexgc growth 3Y-35.26%
ROICexgc growth 5Y-11.95%
ROICexc growth 3Y-38.49%
ROICexc growth 5Y-19.53%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
F-Score7
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 1.28
Debt/FCF 8.92
Debt/EBITDA 3.69
Cap/Depr 92.32%
Cap/Sales 11.25%
Interest Coverage 2.65
Cash Conversion 94.72%
Profit Quality 357.97%
Current Ratio 0.95
Quick Ratio 0.49
Altman-Z 2.43
F-Score7
WACC8.87%
ROIC/WACC0.53
Cap/Depr(3y)148.03%
Cap/Depr(5y)150.65%
Cap/Sales(3y)13.71%
Cap/Sales(5y)12.64%
Profit Quality(3y)282.77%
Profit Quality(5y)224.27%
High Growth Momentum
Growth
EPS 1Y (TTM)59.34%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%24.14%
EPS Next Y23.18%
EPS Next 2Y21.51%
EPS Next 3Y21.15%
EPS Next 5Y18.87%
Revenue 1Y (TTM)5.82%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%6.25%
Revenue Next Year5.32%
Revenue Next 2Y6.73%
Revenue Next 3Y8.71%
Revenue Next 5Y8.45%
EBIT growth 1Y18.65%
EBIT growth 3Y-21.66%
EBIT growth 5Y4.31%
EBIT Next Year101.42%
EBIT Next 3Y38.38%
EBIT Next 5Y26.17%
FCF growth 1Y123.33%
FCF growth 3Y7.25%
FCF growth 5Y29.73%
OCF growth 1Y6.61%
OCF growth 3Y4.07%
OCF growth 5Y20.79%

SARTORIUS AG-VORZUG / SRT3.DE FAQ

What is the ChartMill fundamental rating of SARTORIUS AG-VORZUG (SRT3.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SRT3.DE.


Can you provide the valuation status for SARTORIUS AG-VORZUG?

ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS AG-VORZUG (SRT3.DE). This can be considered as Overvalued.


Can you provide the profitability details for SARTORIUS AG-VORZUG?

SARTORIUS AG-VORZUG (SRT3.DE) has a profitability rating of 3 / 10.


What is the valuation of SARTORIUS AG-VORZUG based on its PE and PB ratios?

The Price/Earnings (PE) ratio for SARTORIUS AG-VORZUG (SRT3.DE) is 52.61 and the Price/Book (PB) ratio is 6.73.


Can you provide the financial health for SRT3 stock?

The financial health rating of SARTORIUS AG-VORZUG (SRT3.DE) is 1 / 10.